Drugs / CS1003
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03809767 | Oct 2018 → Aug 2021 | cancer, lymphoma | CStone Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03475251 | May 2018 → May 2021 | cancer of unknown primary site | CStone Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03523819 | Apr 2018 → Jan 2022 | cancer | CStone Pharmaceuticals | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04194775 | Dec 2019 → Jun 2025 overdue | hepatocellular carcinoma | CStone Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS1003 | “Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma” NCT04194775 ↗ |
| Known as | Antibody cs1003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594536 ↗ |
| Known as | Nofazinlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04194775 ↗ |
| Known as | Recombinant pd-1 mab cs1003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594536 ↗ |
| Action | Inhibit | “Programmed cell death protein 1 inhibitor” CHEMBL4594536 ↗1“Anti-PD-1” NCT03523819 ↗ |
| Modality | Monoclonal antibody | “Anti-PD-1 Monoclonal Antibody CS1003” NCT03475251 ↗ |
| Route | Intravenous | “CS1003 to be intravenously administered at the dose level determined during the dose escalation part” NCT03475251 ↗ |
| Target | PDCD1 | “Programmed cell death protein 1 inhibitor” CHEMBL4594536 ↗ |